128 related articles for article (PubMed ID: 11559555)
41. Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging.
Bains LJ; Baker JH; Kyle AH; Minchinton AI; Reinsberg SA
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):957-65. PubMed ID: 19480975
[TBL] [Abstract][Full Text] [Related]
42. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors.
Dziba JM; Marcinek R; Venkataraman G; Robinson JA; Ain KB
Thyroid; 2002 Dec; 12(12):1063-70. PubMed ID: 12593719
[TBL] [Abstract][Full Text] [Related]
43. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
[TBL] [Abstract][Full Text] [Related]
44. Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging.
Faccioli N; Marzola P; Boschi F; Sbarbati A; D'Onofrio M; Pozzi Mucelli R
Radiol Med; 2007 Apr; 112(3):319-28. PubMed ID: 17440699
[TBL] [Abstract][Full Text] [Related]
45. [Effects of MRI-assayed microvascular permeability on the accumulation of vinorelbine in xenograft tumors].
Raatschen HJ; Fu Y; Rogut V; Simon GH; Sennino B; Wolf KJ; Brasch RC
Rofo; 2010 Feb; 182(2):133-9. PubMed ID: 19862658
[TBL] [Abstract][Full Text] [Related]
46. Parametric imaging of tumor perfusion using flow- and permeability-limited tracers.
Bogin L; Margalit R; Mispelter J; Degani H
J Magn Reson Imaging; 2002 Sep; 16(3):289-99. PubMed ID: 12205585
[TBL] [Abstract][Full Text] [Related]
47. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Salmon HW; Siemann DW
Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
[TBL] [Abstract][Full Text] [Related]
48. Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors.
Artemov D; Solaiyappan M; Bhujwalla ZM
Cancer Res; 2001 Apr; 61(7):3039-44. PubMed ID: 11306485
[TBL] [Abstract][Full Text] [Related]
49. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
50. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
51. Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging.
Eichhorn ME; Becker S; Strieth S; Werner A; Sauer B; Teifel M; Ruhstorfer H; Michaelis U; Griebel J; Brix G; Jauch KW; Dellian M
Cancer Biol Ther; 2006 Jan; 5(1):89-96. PubMed ID: 16357513
[TBL] [Abstract][Full Text] [Related]
52. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.
Hill SA; Chaplin DJ; Lewis G; Tozer GM
Int J Cancer; 2002 Nov; 102(1):70-4. PubMed ID: 12353236
[TBL] [Abstract][Full Text] [Related]
53. Design and Evaluation of Rhein-Based MRI Contrast Agents for Visualization of Tumor Necrosis Induced by Combretastatin A-4 Disodium Phosphate.
Zhang L; Zhang D; Gao M; Jin Q; Jiang C; Wu T; Feng Y; Ni Y; Yin Z; Zhang J
Mol Imaging Biol; 2021 Apr; 23(2):220-229. PubMed ID: 33048270
[TBL] [Abstract][Full Text] [Related]
54. Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma model.
Seiler GS; Ziemer LS; Schultz S; Lee WM; Sehgal CM
Cancer Imaging; 2007 Dec; 7(1):216-23. PubMed ID: 18083651
[TBL] [Abstract][Full Text] [Related]
55. Antineoplastic agents 442. Synthesis and biological activities of dioxostatin.
Pettit GR; Lippert JW; Boyd MR; Verdier-Pinard P; Hamel E
Anticancer Drug Des; 2000 Oct; 15(5):361-71. PubMed ID: 11354312
[TBL] [Abstract][Full Text] [Related]
56. The development of combretastatin A4 phosphate as a vascular targeting agent.
Chaplin DJ; Hill SA
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1491-6. PubMed ID: 12459376
[TBL] [Abstract][Full Text] [Related]
57. Effect of dexamethasone on vascular function in RIF-1 tumors.
Braunschweiger PG; Schiffer LM
Cancer Res; 1986 Jul; 46(7):3299-303. PubMed ID: 3708563
[TBL] [Abstract][Full Text] [Related]
58. The potential of hyperpolarized
Iversen AB; Busk M; Bertelsen LB; Laustsen C; Munk OL; Nielsen T; Wittenborn TR; Bussink J; Lok J; Stødkilde-Jørgensen H; Horsman MR
Acta Oncol; 2017 Nov; 56(11):1626-1633. PubMed ID: 28840759
[TBL] [Abstract][Full Text] [Related]
59. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure.
Ley CD; Horsman MR; Kristjansen PE
Neoplasia; 2007 Feb; 9(2):108-12. PubMed ID: 17356706
[TBL] [Abstract][Full Text] [Related]
60. Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy.
Bohndiek SE; Kettunen MI; Hu DE; Witney TH; Kennedy BW; Gallagher FA; Brindle KM
Mol Cancer Ther; 2010 Dec; 9(12):3278-88. PubMed ID: 21159611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
